Home/Investors/Public Markets Public Markets
Biotech Investor · 24 portfolio companies
Portfolio Companies
| Company | Stage | Valuation | Focus |
|---|
| InventisBio | phase-2 | — | Oncology, Metabolic Diseases |
| Junshi Biosciences | commercial | — | Oncology, Immunology |
| JW Therapeutics | commercial | — | Oncology, Hematology |
| Dizal Pharma | phase-2 | — | Oncology, Immunology |
| Getein Biotech | commercial | — | Diagnostics |
| Zhejiang Orient Gene Biotech | commercial | — | Infectious Disease |
| Yifan Pharmaceutical | commercial | — | Cardiovascular, Metabolic Disease |
| Venus MedTech | commercial | — | Cardiovascular |
| Betta Pharmaceuticals | commercial | — | Oncology, Metabolic |
| Ascletis Pharma | commercial | — | Infectious Disease, Oncology |
| Innovax | commercial | — | Infectious Disease |
| LintonPharm | phase-2 | — | Oncology |
| Lee's Pharmaceutical | commercial | — | Cardiovascular, Oncology |
| Sichuan Haisco Pharmaceutical | commercial | — | Central Nervous System, Oncology |
| Sino Biological | platform | — | Infectious Disease, Oncology |
| Acelyrin | phase-3 | — | Immunology |
| Novogene | commercial | — | Genetics & Genomics, Diagnostics |
| InnoCare | commercial | — | Oncology, Immunology |
| Genetron Health | commercial | — | Oncology, Diagnostics |
| Gan & Lee Pharmaceutical | commercial | — | Metabolic |
| China Biologic Products | commercial | — | Hematology, Biologics |
| CANbridge Pharmaceuticals | phase-3 | — | Rare Disease, Oncology |
| Biostar Pharmaceuticals | commercial | — | Infectious Disease |
| Immunofoco | phase-3 | — | Oncology, Infectious Diseases |